The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function

The 2002 study investigated the role of the transcriptional co-activator cAMP Response Element-Binding Protein-Binding Protein (CBP) in prostate cancer. Researchers found that CBP was expressed in all prostate cancer cell lines tested (LNCaP, PC-3, and DU-145), and its overexpression influenced the balance of nonsteroidal anti-androgens, enhancing their agonistic properties. CBP was also found in benign, premalignant, and malignant prostate tissues from patients, but its expression was lost in three primary tumors and in 2 of 26 lymph node metastases. The study suggested that CBP could play a role in the progression of prostate cancer and the effectiveness of anti-androgen therapies. However, other androgen receptor co-activators might account for diminished antagonism of bicalutamide, indicating a need for further research.